Accès gratuit
Numéro
Med Sci (Paris)
Volume 17, Numéro 12, Décembre 2001
Page(s) 1289 - 1296
Section Articles de Synthèse
DOI https://doi.org/10.1051/medsci/200117121289
Publié en ligne 15 décembre 2001
  1. Malloy PJ, Pike JW, Feldman D. The vitamin D receptor and the syndrome of hereditary 1,25- dihydroxyvitamin D-resistant rickets. Endocrinol Rev 1999; 20 : 156–88.
  2. Feldman D, Glorieux FH, Pike JW. Vitamin D. San Diego : Academic Press, 1997.
  3. Li YC, Pirro AE, Amling M, et al. Targeted ablation of the vitamin D receptor : an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci USA 1997; 94 : 9831–5.
  4. Yoshizawa T, Handa Y, Uematsu Y, et al. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 1997; 16 : 391–6.
  5. Li YC, Amling M, Pirro AE, et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 1998; 139: 4391–6.
  6. Glorieux FH, Arabian A, Delvin EE. Pseudo-vitamin D deficiency : absence of 25-hydroxyvitamin D 1 alpha- hydroxylase activity in human placenta decidual cells. J Clin Endocrinol Metab 1995; 80 : 2255–8.
  7. Shinki T, Shimada H, Wakino S, et al. Cloning and expression of rat 25-hydroxyvitamin D3-1alpha-hydroxylase cDNA. Proc Natl Acad Sci USA 1997; 94 : 12920–5.
  8. St-Arnaud R, Messerlian S, Moir JM, Omdahl JL, Glorieux FH. The 25-hydroxyvitamin D 1-alpha-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J Bone Miner Res 1997; 12 : 1552–9.
  9. Takeyama K, Kitanaka S, Sato T, Kobori M, Yanagisawa J, Kato S. 25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis. Science 1997; 277 : 1827–30.
  10. Fu GK, Lin D, Zhang MY, et al. Cloning of human 25-hydroxyvitamin D-1 alphahydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol Endocrinol 1997; 11 : 1961–70.
  11. Delvin EE, Glorieux FH, Marie PJ, Pettifor JM. Vitamin D dependency : replacement therapy with calcitriol ? J Pediatr 1981; 99 : 26–34.
  12. Reade TM, Scriver CR, Glorieux FH, et al. Response to crystalline 1alpha-hydroxyvitamin D3 in vitamin D dependency. Pediatr Res 1975; 9 : 593–9.
  13. Labuda M, Labuda D, Korab-Laskowska M, et al. Linkage disequilibrium analysis in young populations : pseudo-vitamin D- deficiency rickets and the founder effect in French Canadians. Am J Hum Genet 1996; 59 : 633–43.
  14. Labuda M, Morgan K, Glorieux FH. Mapping autosomal recessive vitamin D dependency type I to chromosome 12q14 by linkage analysis. Am J Hum Genet 1990; 47 : 28–36.
  15. Yoshida T, Monkawa T, Tenenhouse HS, et al. Two novel 1alpha-hydroxylase mutations in French-Canadians with vitamin D dependency rickets type I1. Kidney Int 1998; 54 : 1437–43.
  16. Wang JT, Lin CJ, Burridge SM, et al. Genetics of vitamin D 1alpha-hydroxylase deficiency in 17 families. Am J Hum Genet 1998; 63 : 1694–702.
  17. Smith SJ, Rucka AK, Berry JL, et al. Novel mutations in the 1alpha-hydroxylase (P450c1) gene in three families with pseudovitamin D-deficiency rickets resulting in loss of functional enzyme activity in bloodderived macrophages. J Bone Miner Res 1999; 14 : 730–9.
  18. Kitanaka S, Murayama A, Sakaki T, et al. No enzyme activity of 25-hydroxyvitamin D3 1alpha-hydroxylase gene product in pseudovitamin D deficiency rickets, including that with mild clinical manifestation. J Clin Endocrinol Metab 1999; 84 : 4111–7.
  19. Kitanaka S, Takeyama K, Murayama A, et al. Inactivating mutations in the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. N Engl J Med 1998; 338 : 653–61.
  20. Balsan S. Hereditary pseudo-deficiency rickets or vitamin D-dependency type I. In : Glorieux FH, ed. Rickets. New York : Raven Press, 1991 : 155–63.
  21. Sakaki T, Sawada N, Takeyama K, Kato S, Inouye K. Enzymatic properties of mouse 25-hydroxyvitamin D3 1 alpha-hydroxylase expressed in Escherichia coli . Eur J Biochem 1999; 259 : 731–8.
  22. Sawada N, Sakaki T, Kitanaka S, Takeyama K, Kato S, Inouye K. Enzymatic properties of human 25-hydroxyvitamin D3 1alpha-hydroxylase coexpression with adrenodoxin and NADPH-adrenodoxin reductase in Escherichia coli. Eur J Biochem 1999; 265 : 950–6.
  23. Takeuchi A, Okano T, Kobayashi T. The existence of 25-hydroxyvitamin D3-1 alphahydroxylase in the liver of carp and bastard halibut. Life Sci 1991; 48 : 275–82.
  24. Hollis BW, Roos BA, Draper HH, Lambert PW. Vitamin D and its metabolites in human and bovine milk. J Nutr 1981; 111 : 1240–8.
  25. Brenza HL, Kimmel-Jehan C, Jehan F, et al. Parathyroid hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter. Proc Natl Acad Sci USA 1998; 95 : 1387–91.
  26. Murayama A, Takeyama K, Kitanaka S, Kodera Y, Hosoya T, Kato S. The promoter of the human 25-hydroxyvitamin D3 1 alpha-hydroxylase gene confers positive and negative responsiveness to PTH, calcitonin, and 1 alpha,25(OH)2D3. Biochem Biophys Res Commun 1998; 249 : 11–6.
  27. Murayama A, Takeyama K, Kitanaka S, et al. Positive and negative regulations of the renal 25-hydroxyvitamin D3 1alpha-hydroxylase gene by parathyroid hormone, calcitonin, and 1alpha,25(OH)2D3 in intact animals. Endocrinology 1999; 140 : 2224–31.
  28. Shinki T, Ueno Y, DeLuca HF, Suda T. Calcitonin is a major regulator for the expression of renal 25- hydroxyvitamin D3-1alpha-hydroxylase gene in normocalcemic rats. Proc Natl Acad Sci USA 1999; 96 : 8253–8.
  29. Murayama A, Takeyama K, Asahina T, Kitanaka S, Kato S. Cloning of a novel transcription factor mediating the negative vitamin D responsiveness through the human 25-hydroxyvitamin D-1alpha-hydroxylase nVDRE. J Bone Miner Res 2000; 15 (suppl 1) : S199.
  30. Viville S. Recombinaison homologue : nouveaux vecteurs, nouvelles perspectives. Med Sci 1995; 11 : 735–46.
  31. Dardenne O, Prud’homme J, Arabian A, Glorieux FH, St-Arnaud R. Targeted inactivation of the 25-hydroxyvitamin D3-1α-hydroxylase gene (cyp2781) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology 2001; 142 : 3135–41.
  32. Girasole G, Wang JM, Pedrazzoni M, et al. Augmentation of monocyte chemotaxis by 1 alpha,25-dihydroxyvitamin D3. Stimulation of defective migration of AIDS patients. J Immunol 1990; 145 : 2459–64.
  33. Smith EL, Walworth NC, Holick MF. Effect of 1 alpha,25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol 1986; 86 : 709–14.
  34. Ducy P, Starbuck M, Priemel M, et al. A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev 1999; 13 : 1025–36.
  35. Kinuta K, Tanaka H, Shinohara M, Kato S, Seino Y. Vitamin D is a negative regulating factor in bone mineralization. J Bone Miner Res 2000;15 (suppl 1) : S180.
  36. Gardiner EM, Sims N, Thomas G, et al. Elevated osteoblastic vitamin D receptor in transgenic mice yields stronger bones. Bone 1998; 23 (suppl 5) : S176.
  37. Tarutani M, Itami S, Okabe M, et al. Tissue-specific knockout of the mouse Pig-a gene reveals important roles for GPI-anchored proteins in skin development. Proc Natl Acad Sci USA 1997; 94 : 7400–5.
  38. Horvai A, Palinski W, Wu H, Moulton KS, Kalla K, Glass CK. Scavenger receptor A gene regulatory elements target gene expression to macrophages and to foam cells of atherosclerotic lesions. Proc Natl Acad Sci USA 1995; 92 : 5391–5.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.